Stock IMTX IMMATICS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Immatics N.V.

Equities

IMTX

NL0015285941

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
11.7 USD +19.14% Intraday chart for Immatics N.V. +6.75% +11.11%
May. 15 Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating MT
May. 14 Immatics' Q1 Loss Narrows. Revenue Rises MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immatics: Q1 Earnings Snapshot
AQ
Immatics N : Corporate Presentation May 2024
PU
Immatics Announces First Quarter 2024 Financial Results and Business Update
GL
Immatics N : Corporate Presentation March 2024
PU
Immatics Announces Full Year 2023 Financial Results and Corporate Update
GL
Immatics Announces Pricing of $175 Million Public Offering
GL
Immatics Announces Pricing of $175 Million Public Offering
AQ
Immatics Announces Proposed Public Offering
GL
Immatics Announces Proposed Public Offering
AQ
Immatics: Q3 Earnings Snapshot
AQ
Immatics Announces Third Quarter 2023 Financial Results and Business Update
GL
Immatics Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
AQ
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
GL
Immatics N : ACTengine® IMA203 Clinical Data Update at Society for Melanoma Research Congress, November 2023
PU
Immatics Receives FDA Regenerative Medicine Advanced Therapy Designation for ACTengine IMA203 TCR-T Monotherapy
AQ
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
GL
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
AQ
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
AQ
MODERNA AND IMMATICS ANNOUNCE STRATEGIC MULTI-PLATFORM COLLABORATION TO DEVELOP INNOVATIVE ONCOLOGY THERAPEUTICS
AQ
Immatics N : Corporate Presentation, September 2023
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMTX Stock
  4. News Immatics N.V.
  5. Press Releases